News | News By Subject | News by Disease News By Date | Search News

Multiple sclerosis (MS) News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
How Roche (RHHBY) Fine-Tuned an Old Drug Under a New Name to Keep Making Profits     8/24/2017
BIO2017: Ann Romney Shares Journey Through MS Treatments, Founding of Neurological Research Center     6/21/2017
Why Celgene (CELG) Gets No R-E-S-P-E-C-T, But Should     6/14/2017
How Much is Too Much to Pay for Newly Approved Drugs?     6/7/2017
Roche (RHHBY)'s New MS Drug Linked to Deadly Brain Infection     5/30/2017
What a Day! Genentech (RHHBY) Lands FDA Approval for First Drug to Treat Severe Multiple Sclerosis     4/4/2017
Perrigo (PRGO) Cuts 750 Jobs, Sells MS Drug Royalties for $2.85 Billion and Loses CFO to Amgen (AMGN)     3/1/2017
This Drug Could Rattle Biogen (BIIB) and Be the Next Billion-Dollar Blockbuster for Celgene (CELG)     2/23/2017
The 7 Worst Clinical Disasters of 2016     12/27/2016
3 Reasons That Make Biogen (BIIB) the King of a Crumbling Empire     11/14/2016
Opexa Therapeutics (OPXA) Stock Tanks After Failed MS Trial, Cuts 40% Staff     11/2/2016
Teva (TEVA) Stock Plummets After Two Patents are Invalidated by Mylan (MYL)     8/25/2016
Novartis AG (NVS) Touts Phase III Data for MS Drug Siponimod     8/25/2016
Speedy Review for Genentech (RHHBY)’s OCREVUS, Action Date December 28     6/29/2016
Biogen (BIIB) Loses $8 Billion in Market Value in One Day After Failed Trial     6/8/2016

News from Around the Web
Vitamin D Levels May Help Predict Risk Of MS, Neurology Reveals     9/15/2017
Here's Why Multiple Sclerosis Drugs Cost So Much     8/24/2017
Liver Safety Issues Lead The EMA To Restrict Biogen (BIIB)'s MS Drug     7/10/2017
A Blood Test For Multiple Sclerosis? Expect One In Late May     5/17/2017
How Genentech (RHHBY) Could Be A New Threat For Biogen (BIIB)     5/10/2017
How Much Biogen (BIIB)'s Top-Selling MS Drug Sales Could Fall by 2020     4/10/2017
Could Non-Invasive Brain Stimulation With Cognitive Training Reduce MS Symptoms? New York University’s Langone Medical Center Study     3/2/2017
GW Pharma (GWPH) Is Set To Benefit As Cannabis Takes On Cancer     2/10/2017
Multiple Sclerosis Drug Triggers Severe Adverse Events, Lancet Neurology Reveals     1/20/2017
Celgene (CELG) Could Dethrone Biogen (BIIB) in Multiple Sclerosis     9/29/2016
Brain Inflammation Linked To Depression In MS Patients, King's College London Study     7/8/2016
Poor Sleep And Thinking Problems In MS Patients, University of Michigan Study     6/21/2016
Allergy Med Might Also Fight MS-Linked Eye Damage, UCSF Study     4/14/2016
Binging On Coffee May Cut Your MS Risk, Study Published In BMJ     3/7/2016
Why It Feels So Good To Scratch An Itch, Published In Proceedings Of The Entomological Society Of Washington     2/29/2016

Press Releases
touchNEUROLOGY Release: New Review Of The Emerging Role Of Teriflunomide In The Treatment Of Multiple Sclerosis     9/19/2017
touchNEUROLOGY Release: New Review Considers Selective Targeting Of T And B Cell Populations By Alemtuzumab In The Treatment Of Multiple Sclerosis     9/19/2017
Life Science Tech Company IQuity Now Receiving Physician Orders For First RNA-Based Blood Test For Multiple Sclerosis     9/19/2017
TG Therapeutics (TGTX) Announces The Phase III ULTIMATE Trials Evaluating TG-1101 In Patients With Multiple Sclerosis Are Now Open For Enrollment     9/15/2017
Novartis AG (NVS) Landmark Phase III Trial Shows Fingolimod Significantly Reduces Relapses In Children And Adolescents With MS     9/5/2017
EMD Serono Release: Investigational Cladribine Tablets Demonstrates Sustained Disease Control Over 4 Years With Maximum Of 20 Days Oral Treatment     9/5/2017
MediciNova, Inc. Announces The Abstract From The MN-166 (Ibudilast) SPRINT-MS Phase 2b Study In Progressive MS - Including Top Line Data - Was Selected As A Platform Presentation For Late-Breaking Presentation At The 7th Joint ECTRIMS - ACTRIMS Meeting On October 28, 2017 In Paris, France     8/30/2017
GeNeuro And Servier Announce Six-Month Results From CHANGE-MS Phase IIb Study In Multiple Sclerosis     8/28/2017
Novartis AG (NVS) Launches First Large-Scale Research Study In Multiple Sclerosis That Allows Participants To Contribute From Smartphones     8/22/2017
TetraPhase (TTPH) Announces Submission And Validation Of IV Eravacycline Marketing Authorization Application By EMA     8/17/2017
TG Therapeutics (TGTX) Announces Special Protocol Assessment (SPA) Agreement With The FDA For A Phase III Program Of TG-1101 (Ublituximab) For Patients With Multiple Sclerosis (MS)     8/1/2017
CRF Health Collaborates With University Hospital Basel To Create Electronic Version Of Neurostatus-Expanded Disability Status Scale Form For Multiple Sclerosis Clinical Trials     7/13/2017
TG Therapeutics (TGTX) Recaps Preliminary Results From Ongoing Phase II Study Of TG-1101 (Ublituximab) In Patients With Multiple Sclerosis At The 3rd Congress Of The European Academy Of Neurology     6/26/2017
New Data At EAN Show Genentech (RHHBY)’s Ocrevus (Ocrelizumab) Significantly Reduced Multiple Measures Of Disease Progression In Relapsing And Primary Progressive Multiple Sclerosis     6/23/2017
Mallinckrodt (MNK) Highlights First Patients In Company-Sponsored Prospective Observational Registry On The Use Of H.P. Acthar Gel (Repository Corticotropin Injection) Following Acute Multiple Sclerosis Relapse     5/26/2017

//-->